X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (105) 105
male (62) 62
female (59) 59
middle aged (53) 53
aged (51) 51
venous thromboembolism (48) 48
prevention (40) 40
thrombosis (40) 40
thromboembolism (38) 38
hematology (37) 37
adult (36) 36
anticoagulants - therapeutic use (36) 36
risk factors (36) 36
peripheral vascular disease (34) 34
anticoagulants (33) 33
cancer (32) 32
treatment outcome (31) 31
neoplasms - complications (28) 28
prophylaxis (28) 28
deep-vein thrombosis (27) 27
abridged index medicus (26) 26
venous thromboembolism - prevention & control (26) 26
rivaroxaban (24) 24
double-blind method (23) 23
oncology (23) 23
surgery (21) 21
hemorrhage - chemically induced (20) 20
medicine, general & internal (20) 20
anticoagulants - administration & dosage (19) 19
drug therapy (19) 19
venous thromboembolism - drug therapy (19) 19
warfarin (19) 19
anticoagulants - adverse effects (18) 18
molecular-weight heparin (18) 18
venous thrombosis (18) 18
care and treatment (17) 17
risk (17) 17
stroke (17) 17
aged, 80 and over (16) 16
bleeding (16) 16
heparin (16) 16
heparin, low-molecular-weight - therapeutic use (16) 16
mortality (16) 16
pulmonary embolism (16) 16
venous thrombosis - prevention & control (16) 16
administration, oral (15) 15
atrial fibrillation (15) 15
enoxaparin (15) 15
patients (15) 15
pulmonary embolism - prevention & control (15) 15
pulmonary-embolism (15) 15
recurrence (15) 15
venous thromboembolism - etiology (15) 15
dosage and administration (14) 14
risk assessment (14) 14
thromboprophylaxis (14) 14
fibrinolytic agents - therapeutic use (12) 12
health aspects (12) 12
life sciences (12) 12
postoperative complications - prevention & control (12) 12
prospective studies (12) 12
research (12) 12
time factors (12) 12
unfractionated heparin (12) 12
health risk assessment (11) 11
incidence (11) 11
registries (11) 11
veins & arteries (11) 11
venous thromboembolism - epidemiology (11) 11
cardiac & cardiovascular systems (10) 10
follow-up studies (10) 10
management (10) 10
neoplasms - drug therapy (10) 10
neoplasms - mortality (10) 10
pulmonary embolism - mortality (10) 10
therapy (10) 10
chemotherapy (9) 9
deep vein thrombosis (9) 9
hemorrhage (9) 9
metaanalysis (9) 9
randomized controlled trials as topic (9) 9
risk-factors (9) 9
survival analysis (9) 9
thromboembolism - prevention & control (9) 9
usage (9) 9
venous thrombosis - epidemiology (9) 9
adolescent (8) 8
analysis (8) 8
anticoagulation (8) 8
drug administration schedule (8) 8
embolisms (8) 8
guidelines (8) 8
heparin, low-molecular-weight - administration & dosage (8) 8
hospitals (8) 8
practice guidelines as topic (8) 8
prognosis (8) 8
pulmonary embolism - epidemiology (8) 8
registry (8) 8
safety (8) 8
thromboembolism - etiology (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 5, p. e63479
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 14, pp. 1319 - 1330
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 7, pp. 615 - 624
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2008, Volume 358, Issue 26, pp. 2765 - 2775
.... Huisman, M.D., Ph.D., Ajay K. Kakkar, M.D., Ph.D., Tiemo J. Bandel, M.D., Horst Beckmann, Ph.D., Eva Muehlhofer, M.D., Frank Misselwitz, M.D., Ph.D., and William... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 23, pp. 2167 - 2177
In this clinical trial of hospitalized medically ill patients, extended thromboprophylaxis (30 days) with apixaban had similar efficacy to that of a shorter... 
REPLACEMENT | MEDICINE, GENERAL & INTERNAL | VENOUS THROMBOEMBOLISM | PULMONARY-EMBOLISM | DOUBLE-BLIND | PREVENTION | PLACEBO-CONTROLLED TRIAL | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Venous Thromboembolism - mortality | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thromboembolism - epidemiology | Pyrazoles - adverse effects | Acute Disease | Double-Blind Method | Drug Administration Schedule | Hemorrhage - epidemiology | Risk Factors | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Treatment Outcome | Hospitalization | Anticoagulants - adverse effects | Heart Failure - drug therapy | Pulmonary Embolism - mortality | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Respiratory Insufficiency - drug therapy | Drugs | Enoxaparin | Dosage and administration | Venous thrombosis | Product/Service Evaluations | Thrombolytic drugs | Comparative analysis | Drug therapy | Heart failure | Fees & charges | Anticoagulants | Compression | Prophylaxis | Congestive heart failure | Thrombosis | Bleeding | Embolism | Compression therapy | Ultrasonic imaging | Hospitals | Safety | Thromboembolism | Health risk assessment | Ultrasound | Respiratory Insufficiency | Hemorrhage | Life Sciences | Venous Thromboembolism | Heart Failure | Pyrazoles | Pyridones | Human health and pathology | Pulmonary Embolism
Journal Article